• / Free eNewsletters & Magazine
  • / My Account
Home>Authors>Damien Conover

Damien Conover

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  5. Research
  1. J&J's Strong 2Q Led by Pharmaceuticals

    Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover .

  2. A Shift in Health-Care M&A Activity

    Recent deals have been driven more by tax strategies than therapeutic synergies.

  3. Prescribe to Pharma for Emerging-Markets Growth

    Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover .

  4. Johnson & Johnson's Pharma Group Leading the Way

    The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover .

  5. Pfizer-Astra Deal Will Get Done

    Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover .

  6. Health Care a Leader in Moat Stocks

    The health-care sector has a higher volume of moat firms compared with other industries, and companies' patent and brand power deliver very strong returns on capital.

  7. The Friday Five

    This week: Financial-services firms post lukewarm earnings, two tech giants strike a deal, Time Warner turns down a foxy offer, and more.

  8. The Friday Five

    Draghi drops a hint, Whole Foods takes a hit, and Alibaba's impending IPO raises questions for Yahoo.

  9. The Sector Is Fairly Valued, but These Stocks Are Not

    A handful of health-care names are selling at premiums now, but buying opportunities are surfacing, as well.

  10. The Friday Five

    Bank of America makes a boo-boo, Twitter shares are still flying too high, Morningstar heads to Omaha, and more.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.